Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
EMERYVILLE, Calif., April 26, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report first quarter 2018 financial results on Thursday, May 3, 2018, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
Investor Conference Call and Webcast
The conference call can be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers. The webcast can be accessed live via the investor section of the Adamas website at http://ir.adamaspharma.com/events-presentations and will be available for replay until June 3, 2018.
About Adamas Pharmaceuticals, Inc.
Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The company is focused on the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only medicine approved by the U.S. Food and Drug Administration for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and delivering on its pipeline of differentiated investigational programs. Those programs include: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.
Contact: Ashleigh Barreto Director, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. 510-450-3567 [email protected]
